Liu Y - Search Results

1

Topical Lyophilized Targeted Lipid Nanoparticles in the Restoration of Skin Barrier Function following Burn Wound.

Li J, Ghatak S, El Masry MS, Das A, Liu Y, Roy S, Lee RJ, Sen CK. Li J, et al. Among authors: liu y. Mol Ther. 2018 Sep 5;26(9):2178-2188. doi: 10.1016/j.ymthe.2018.04.021. Epub 2018 Apr 27. Mol Ther. 2018. PMID: 29802017 Free PMC article.

2

Lipid-Albumin Nanoparticles (LAN) for Therapeutic Delivery of Antisense Oligonucleotide against HIF-1α.

Li H, Quan J, Zhang M, Yung BC, Cheng X, Liu Y, Lee YB, Ahn CH, Kim DJ, Lee RJ. Li H, et al. Among authors: liu y. Mol Pharm. 2016 Jul 5;13(7):2555-62. doi: 10.1021/acs.molpharmaceut.6b00363. Epub 2016 Jun 16. Mol Pharm. 2016. PMID: 27253378

3

Lipid Nanoparticles Loaded with an Antisense Oligonucleotide Gapmer Against Bcl-2 for Treatment of Lung Cancer.

Cheng X, Liu Q, Li H, Kang C, Liu Y, Guo T, Shang K, Yan C, Cheng G, Lee RJ. Cheng X, et al. Among authors: liu y, liu q. Pharm Res. 2017 Feb;34(2):310-320. doi: 10.1007/s11095-016-2063-5. Epub 2016 Nov 28. Pharm Res. 2017. PMID: 27896589

4

Folate receptor-targeted lipid-albumin nanoparticles (F-LAN) for therapeutic delivery of an Akt1 antisense oligonucleotide.

Li H, Liu Y, Chen L, Liu Q, Qi S, Cheng X, Lee YB, Ahn CH, Kim DJ, Lee RJ. Li H, et al. Among authors: liu y, liu q. J Drug Target. 2018 Jun-Jul;26(5-6):466-473. doi: 10.1080/1061186X.2018.1433678. Epub 2018 Feb 8. J Drug Target. 2018. PMID: 29376449

5

A novel protein-drug conjugate, SSH20, demonstrates significant efficacy in caveolin-1-expressing tumors.

Robb R, Kuo JC, Liu Y, Corrales-Guerrero S, Cui T, Hegazi A, Nagy G, Lee RJ, Williams TM. Robb R, et al. Among authors: liu y. Mol Ther Oncolytics. 2021 Aug 6;22:555-564. doi: 10.1016/j.omto.2021.07.013. eCollection 2021 Sep 24. Mol Ther Oncolytics. 2021. PMID: 34553040 Free PMC article.

6

T7 Peptide-Conjugated Lipid Nanoparticles for Dual Modulation of Bcl-2 and Akt-1 in Lung and Cervical Carcinomas.

Cheng X, Yu D, Cheng G, Yung BC, Liu Y, Li H, Kang C, Fang X, Tian S, Zhou X, Liu Q, Lee RJ. Cheng X, et al. Among authors: liu y, liu q. Mol Pharm. 2018 Oct 1;15(10):4722-4732. doi: 10.1021/acs.molpharmaceut.8b00696. Epub 2018 Sep 7. Mol Pharm. 2018. PMID: 30138565

7

Designer lipids advance systemic siRNA delivery.

Liu Y, Huang L. Liu Y, et al. Mol Ther. 2010 Apr;18(4):669-70. doi: 10.1038/mt.2010.39. Mol Ther. 2010. PMID: 20357780 Free PMC article. No abstract available.

8

Targeted delivery of epirubicin to tumor-associated macrophages by sialic acid-cholesterol conjugate modified liposomes with improved antitumor activity.

Zhou S, Zhang T, Peng B, Luo X, Liu X, Hu L, Liu Y, Di D, Song Y, Deng Y. Zhou S, et al. Among authors: liu y, liu x. Int J Pharm. 2017 May 15;523(1):203-216. doi: 10.1016/j.ijpharm.2017.03.034. Epub 2017 Mar 20. Int J Pharm. 2017. PMID: 28336455

9

Programmed pH/reduction-responsive nanoparticles for efficient delivery of antitumor agents in vivo.

Chen WL, Yang SD, Li F, Qu CX, Liu Y, Wang Y, Wang DD, Zhang XN. Chen WL, et al. Among authors: liu y. Acta Biomater. 2018 Nov;81:219-230. doi: 10.1016/j.actbio.2018.09.040. Epub 2018 Sep 26. Acta Biomater. 2018. PMID: 30267887

10

Doxorubicin and siRNA-PD-L1 co-delivery with T7 modified ROS-sensitive nanoparticles for tumor chemoimmunotherapy.

Wan WJ, Qu CX, Zhou YJ, Zhang L, Chen MT, Liu Y, You BG, Li F, Wang DD, Zhang XN. Wan WJ, et al. Among authors: liu y. Int J Pharm. 2019 Jul 20;566:731-744. doi: 10.1016/j.ijpharm.2019.06.030. Epub 2019 Jun 15. Int J Pharm. 2019. PMID: 31212055

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

209,063 results

Search Page

Filters